Rallybio and Avenzo Merge to Advance Oncology Pipeline with $215M Financing
NEW HAVEN, Conn. & SAN DIEGO, Calif., June 2, 2026 Rallybio Corporation and Avenzo Therapeutics announced a definitive merger...
AVZO-021
Advertisement
Avenzo Reports Promising Phase 1 Data for AVZO-021 in HR+ Breast Cancer
SAN DIEGO, Calif., June 1, 2026 Avenzo Therapeutics announced updated clinical results from the Phase 1 portion of its...
Protagonist to Showcase Phase 3 VERIFY and Long-Term Rusfertide Data at EHA 2026
NEWARK, Calif., June 1, 2026 Protagonist Therapeutics announced that four abstracts featuring rusfertide in polycythemia vera (PV) will be...
Avenzo Therapeutics Advances Dual CDK Inhibitor Breast Cancer Study
SAN DIEGO, Calif., April 28, 2026 Avenzo Therapeutics, Inc. has announced the initiation of the combination cohort in its...
Advertisement
